Oramed Pharmaceuticals Announces Executive and Board Changes
Ticker: ORMP · Form: 8-K · Filed: May 13, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.012 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, management-transition
TL;DR
Oramed shakes up leadership: new CEO, CFO, and board members appointed.
AI Summary
Oramed Pharmaceuticals Inc. announced on May 10, 2024, a series of executive and board changes. This includes the appointment of Dr. Michal Y. Yarkoni as Chief Executive Officer and Mr. Boaz Weiss as Chief Financial Officer. Additionally, the company elected Ms. Tamar Y. Yarkoni and Mr. David Yarkoni to its Board of Directors.
Why It Matters
These leadership transitions at Oramed Pharmaceuticals could signal a new strategic direction for the company, potentially impacting its drug development pipeline and future financial performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — Registrant
- Dr. Michal Y. Yarkoni (person) — Appointed Chief Executive Officer
- Mr. Boaz Weiss (person) — Appointed Chief Financial Officer
- Ms. Tamar Y. Yarkoni (person) — Elected to Board of Directors
- Mr. David Yarkoni (person) — Elected to Board of Directors
FAQ
Who has been appointed as the new Chief Executive Officer of Oramed Pharmaceuticals?
Dr. Michal Y. Yarkoni has been appointed as the new Chief Executive Officer.
Who is the new Chief Financial Officer?
Mr. Boaz Weiss has been appointed as the new Chief Financial Officer.
When did these changes become effective?
The earliest event reported is dated May 10, 2024.
Who has been elected to the Board of Directors?
Ms. Tamar Y. Yarkoni and Mr. David Yarkoni have been elected to the Board of Directors.
What is Oramed Pharmaceuticals' state of incorporation?
Oramed Pharmaceuticals Inc. is incorporated in Delaware.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-05-10 18:00:51
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Te
Filing Documents
- ea0205772-8k_oramed.htm (8-K) — 24KB
- 0001213900-24-041847.txt ( ) — 193KB
- ormp-20240510.xsd (EX-101.SCH) — 3KB
- ormp-20240510_lab.xml (EX-101.LAB) — 33KB
- ormp-20240510_pre.xml (EX-101.PRE) — 22KB
- ea0205772-8k_oramed_htm.xml (XML) — 4KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 10, 2024, David Silberman, the Chief Financial Officer, Treasurer and Secretary (the "CFO") of Oramed Pharmaceuticals Inc. (the "Company"), resigned from his positions with the Company for personal reasons, effective as of July 12, 2024. The Company has initiated a search process to appoint a new CFO. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO May 10, 2024 2